More recently, it was also developed a new monoclonal anti-syndecan-1 antibody, VIS832, to use in multiple myeloma therapy, and it was shown to induce potent NK cell-mediated antibody-dependent cellular cytotoxicity and macrophage-mediated antibody-dependent cellular phagocytosis against myeloma cells either sensitive or resistant to current therapies (143). Here, SDC1 is linked to plasma cell myeloma.